Enveric Biosciences, Inc. (ENVB)
| Market Cap | 8.41M +138.7% |
| Revenue (ttm) | n/a |
| Net Income | -11.58M |
| EPS | -17.16 |
| Shares Out | 3.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 96,446 |
| Open | 2.320 |
| Previous Close | 2.320 |
| Day's Range | 2.200 - 2.410 |
| 52-Week Range | 1.710 - 17.640 |
| Beta | 1.23 |
| Analysts | Buy |
| Price Target | 120.00 (+5,151.64%) |
| Earnings Date | May 15, 2026 |
About ENVB
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for ENVB stock is "Buy" and the 12-month stock price target is $120.0.
News
Enveric Biosciences reports preclinical results from analysis of EB-003
Enveric Biosciences (ENVB) announced “promising” results from preclinical in vitro experiments evaluating the risk for phototoxicity, which indicated no photoreactive potential for EB-003, further der...
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psyc...
Enveric Biosciences reports Q1 EPS ($1.08) vs. ($14.58) last year
“Our progress in the first quarter of 2026 reflects continued execution against our core mission of developing therapeutics capable of addressing the significant unmet need in mental health,” said Jos...
Enveric Biosciences sees cash runway into 1Q27
“In April 2026, Enveric completed a private placement expected to generate gross proceeds of up to $13.9 million, including $5.0 million received at closing, and assuming full exercise of the…
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychi...
Enveric issued U.S. patent for methods of treating psychiatric disorders
Enveric Biosciences (ENVB) announced that the United States Patent and Trademark Office issued to Enveric US Patent No. 12,605,361, titled, “Carboxylated Psilocybin Derivatives and Methods of Using,” ...
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psyc...
Enveric Biosciences highlights preclinical data for EB-003
Enveric Biosciences (ENVB) highlighted preclinical data for its lead candidate, EB-003, a dual 5-HT2A and 5-HT1B modulator, in which a single dose of EB-003 significantly reduced context-induced freez...
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psyc...
Enveric Biosciences trading resumes
09:38 EDT Enveric Biosciences (ENVB) trading resumes
Enveric Biosciences trading halted, volatility trading pause
09:33 EDT Enveric Biosciences (ENVB) trading halted, volatility trading pause
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listing SARASOTA, Fla., April 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc.,...
Enveric Biosciences files to sell 6.82M shares of common stock
19:25 EDT Enveric Biosciences (ENVB) files to sell 6.82M shares of common stock
3 Penny Stocks to Watch Now, 4/21/26
Penny stocks are inexpensive shares that usually trade below $5 apiece and are most often issued by companies with market capitalization of roughly $300 million or less. Enveric Biosciences ($ENVB),…
Enveric Biosciences to Participate in a Panel Discussion at Needham's Virtual Psychedelics Forum
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psyc...
Psychedelic drug makers rally as Trump orders FDA to expedite reviews
Shares of psychedelic drug developers rose in premarket trading on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews of psychedelic dr...
Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to addres...
Enveric Biosciences prices $13.9M at-the-market offering
Enveric Biosciences (ENVB) announced that it has entered into definitive agreements for the purchase and sale of 2,222,223 shares of its common stock, Series I warrants to purchase up to…
Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to addres...
Enveric Biosciences secures new U.S. patent for its EVM301 series
Enveric Biosciences (ENVB) announced that on March 17, 2026, it received U.S. Patent No. 12,577,232 from the United States Patent and Trademark Office, USPTO, pertaining to its EVM301 Series of…
Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psyc...
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychi...
Enveric Biosciences announces registration of five trademarks in Canada
Enveric Biosciences (ENVB) announced that the Canadian Intellectual Property Office has registered five of the company’s trademarks, including its house marks, Enveric and Enveric Biosciences. In addi...
Enveric Biosciences Announces Registration of Five Trademarks
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psyc...
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psyc...